SVP and General Manager, U.S. Cardiovascular, Immunology and Oncology
Bristol Myers Squibb

In this role, Adam heads a business unit that contributed more than one third of the company’s total revenue in 2020. He leads an organization of more than 2,500 employees that have delivered transformational medicines such as Eliquis, Opdivo, Yervoy, Zeposia and Orencia. He is passionate about cultivating a diverse and inclusive culture that prioritizes its people, performance, customers and, above all else, patients.

Adam is an experienced leader who has held numerous senior strategic and operational roles across the company. In his most recent role, he headed the company’s U.S. Oncology business, which, by revenue produced, was the single largest therapeutic division with Bristol Myers Squibb during his tenure. In 2014, he led the Worldwide Oncology Commercialization team, overseeing the launch of Opdivo, which now generates more than $1B a quarter and is widely recognized as one of the most successfully launched oncology products in history. Adam was instrumental in the design and creation of the company’s Integrated Oncology operating model to drive speed and success for marketed and pipeline oncology assets.

Adam’s full biopharma career extends more than 20 years across commercial, market access, sales and operations. He has held a number of commercial leadership positions at Bristol Myers Squibb.

He resides in Lawrenceville, NJ with his wife Candice, and two boys Andrew and Jack.